Literature DB >> 908750

The properties of immune complexes formed by human antibodies to factor VIII.

J Lazarchick, L W Hoyer.   

Abstract

Although human antibodies to Factor VIII inactivate its procoagulant activity, they do not form immunoprecipitates when tested with this antigen. To understand this observation, we have examined the interaction of normal human Factor VIII with four high-titer human anti-Factor VIII, two from transfused hemophiliacs and two "spontaneous" antibodies from nonhemophilic individuals. An estimate of the size of complexes formed by these antibodies has been obtained by agarose gel filtration of mixtures of anti-Factor VIII with cryoprecipitate. Complexed anti-Factor VIII was detected by the method of Allain and Frommel: acid dissociation of complexes at pH 3.5. Complexed anti-Factor VIII was detected in column fractions eluting between the void volume and those which correspond to the elution volume of human IgG. In contrast, Factor VIII procoagulant activity was restricted to void volume fractions when separations were carried out in antigen excess, and free anti-Factor VIII was limited to late-eluting fractions when separations were carried out in antibody excess. A small proportion of the complexed anti-Factor VIII was present in void volume fractions; the quantity was directly related to the ratio of antibody to antigen.Thus, although some complexed anti-Factor VIII is detected in void volume fractions, as would be expected for complexes formed with a very large plasma protein, most immune complexes elute in fractions that indicate interaction with a smaller antigen. These findings suggest that human anti-Factor VIII inactivates procoagulant activity by forming a complex with a small, apparently univalent, component of Factor VIII. This property may prevent immunoprecipitate formation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 908750      PMCID: PMC372459          DOI: 10.1172/JCI108858

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Studies on the nature of the circulating anticoagulant directed against antihemophilic factor: with notes on an assay for anthemophilic factor.

Authors:  R T BRECKENRIDGE; C D RATNOFF
Journal:  Blood       Date:  1962-08       Impact factor: 22.113

2.  Thrombin activation of factor VIII: the effect of inhibitors.

Authors:  M E Rick; L W Hoyer
Journal:  Br J Haematol       Date:  1977-08       Impact factor: 6.998

3.  Antibodies to factor VIII. I. Variations in stability of antigen-antibody complexes in hemophilia A.

Authors:  J P Allain; D Frommel
Journal:  Blood       Date:  1973-09       Impact factor: 22.113

4.  Immunologic properties of antihemophilic factor.

Authors:  L W Hoyer
Journal:  Prog Hematol       Date:  1973

5.  Evidence that factor VIII and the ristocetin aggregating factor (VIIIRist) are separate molecular entities.

Authors:  C Hougie; R B Sargeant; J E Brown; R F Baugh
Journal:  Proc Soc Exp Biol Med       Date:  1974-10

6.  Von Willebrand factor: dissociation from antihemophilic factor procoagulant activity.

Authors:  H J Weiss; I W Hoyer
Journal:  Science       Date:  1973-12-14       Impact factor: 47.728

7.  Circulating anticoagulants to factor VIII. Immunochemical studies and clinical response to factor VIII concentrates.

Authors:  S J Robboy; E J Lewis; P H Schur; R W Colman
Journal:  Am J Med       Date:  1970-12       Impact factor: 4.965

8.  Characterization of human anti-factor VIII antibodies purified by immune complex formation.

Authors:  J M Lavergne; D Meyer; H Reisner
Journal:  Blood       Date:  1976-12       Impact factor: 22.113

9.  Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.

Authors:  H J Weiss; J Rogers; H Brand
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

10.  Factor VIII coagulant activity and factor VIII-like antigen: independent molecular entities.

Authors:  T S Zimmerman; T S Edgington
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

View more
  4 in total

1.  Two distinct forms of Factor VIII coagulant protein in human plasma. Cleavage by thrombin, and differences in coagulant activity and association with von Willebrand factor.

Authors:  M J Weinstein; L E Chute
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

Review 2.  Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Authors:  C H Miller
Journal:  Haemophilia       Date:  2018-02-15       Impact factor: 4.287

3.  Immunoradiometric measurement of the factor VIII procoagulant antigen.

Authors:  J Lazarchick; L W Hoyer
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

4.  Circulating immune complexes containing anti-VIII antibodies in multi-transfused patients with haemophilia A.

Authors:  M D Kazatchkine; Y Sultan; E J Burton-Kee; J F Mowbray
Journal:  Clin Exp Immunol       Date:  1980-02       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.